Former attorney general of Louisiana Charles C. Foti, Jr., along with the law firm Kahn Swick & Foti, LLC (KSF), is looking into the potential acquisition of Marinus Pharmaceuticals, Inc. (NasdaqGM: MRNS).
Read More: https://www.tipranks.com/news/blurbs/buy-rating-on-marinus-pharmaceuticals-backed-by-ztalmys-market-success-and-promising-tsc-drug-development?utm_source=alphanewsstream.com&utm_medium=referral
A class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. (MRNS) with a deadline of August 5, 2024 to join. Levi & Korsinsky can be contacted for more information.
In New York on June 28, 2024, Bragar Eagel & Squire, P.C., a well-known legal firm specializing in shareholder rights, alerts investors about ongoing class action lawsuits.
In New York on June 28, 2024, Bragar Eagel & Squire, P.C., a well-known law firm specializing in shareholder rights, is reminding investors about ongoing class action lawsuits.
Robbins LLP is alerting investors that a shareholder has filed a class action lawsuit on behalf of those who bought Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) securities.
A nationally recognized stockholder rights law firm, Bragar Eagel & Squire, P.C., has announced the filing of a class action lawsuit against Marinus on June 06, 2024.
The law firm Bernstein Liebhard LLP is asking if you own or have owned shares of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) and if you bought them between March 17…
Marinus Pharmaceuticals, Inc. is facing a class action lawsuit filed by a shareholder, as announced by Robbins LLP on June 5, 2024.
Stay updated with the latests analysis and insights fromm etfsector.com